Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Brown is employed by Intermountain Healthcare (IHC Health Services, Inc). In the last 2 years IHC Health Services, Inc has received compensation from Ikaria Inc for a clinical trial contract for which Dr Brown is the principal investigator. In addition, Dr Brown has received compensation for time and travel from United Therapeutics for attendance at advisory board meetings. Dr Elliott is employed by Intermountain Healthcare (IHC Health Services, Inc). In the last 3 years IHC Health Services, Inc has received compensation for clinical trial contracts (on which Dr Elliott is the Principal Investigator) from Actelion Pharmaceuticals Ltd, Bayer Corp, GeNo, Gilead, and United Therapeutics Corp. IHC Health Service Inc has also received or will receive compensation from LungRx for Dr Elliott’s travel and consultancy on the BEAT study. During this same time period, Dr Elliott received compensation for time and travel from Ikaria Inc as chair of the steering committee for the INOPulse study and from Co-Therix as a steering committee member. Dr Rosenzweig has received honoraria for advisory panels from Actelion Pharmaceuticals Ltd and United Therapeutics Corp in the past 3 years and is a consultant for Ikaria, Inc on a clinical research trial. Dr Bayrak-Toydemir is employed by ARUP Laboratories. Dr Hemnes has received research funding from the National Institutes of Health, United Therapeutics Corp, and Pfizer Inc, and has served as a consultant to Actelion Pharmaceuticals Ltd, Pfizer Inc, and United Therapeutics Corp. Drs Best, Austin, Chung, Borczuk, Mao, Cahill, Tazelaar, Leslie, and Robbins and Ms Sumner have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.